Georgetown University Medical Center licenses 'theranostic' for development
January 24, 2012 in CancerGeorgetown University Medical Center (GUMC) has licensed worldwide rights of a potential novel cancer therapy and diagnostic, or "theranostic," to BioMetrx, LLC. The agent was invented by two Georgetown researchers.
GUMC's license agreement with BioMetrx, LLC, a Maryland-headquartered biotechnology company, expedites the translation of the agent, Rasstore, from the laboratory to the clinical setting for further investigation as a potential new therapy.
Rasstore is named for the novel way it could potentially restore the body's natural ability to suppress tumor cells, utilizing the tumor suppressor gene RASSF1A. The agent was invented by Milton Brown, M.D., Ph.D., director of GUMC's Drug Discovery Program, and Partha Banerjee, Ph.D., a world recognized expert on RASSF1A and tumor suppression, also at GUMC.
"It's rewarding for Partha and me to see an agent progress from concept to where we are today on the verge of completing pre-clinical IND enabling studies for a new agent which we believe has applications in prostate cancer and possibly other cancers as well," said Brown, who holds the Edwin H. Richard and Elisabeth Richard von Matsch Endowed Chair in Experimental Therapeutics and is an associate professor at Georgetown Lombardi Comprehensive Cancer Center.
"Rasstore exemplifies the high-quality, early-stage technologies emerging from Georgetown's robust drug discovery program," says Claudia Stewart, vice president of technology commercialization at Georgetown. "Our commercial relationship with BioMetrx represents the process in universities that harnesses the enthusiasm of seasoned entrepreneurs who form a company around the technology, raise funds and then leverage the technical expertise of the inventors to advance the technology...the start up process."
BioMetrx has begun raising the capital required to support clinical investigation.
"We believe Rasstore will be very attractive to other pharmaceutical companies," says John Wells, BioMetrx's Executive Vice President for Global Operations. "This agent has the potential to enhance existing therapeutics because of its potential to restore the body's natural tumor suppression capability."
Provided by
Georgetown University Medical Center
-
Investigational agent shows promise in reducing spread of prostate cancer
Apr 29, 2011 |
not rated yet |
0
-
Historic gene therapy trial to treat Alzheimer's disease underway at Georgetown
Sep 22, 2009 |
not rated yet |
0
-
Investigational agent reduces tumor resistance to breast cancer therapy
Jan 06, 2010 |
not rated yet |
0
-
Chemopreventive isothiocyanates selectively depletes mutant p53 in tumor cells
Apr 20, 2009 |
not rated yet |
0
-
Researchers highlight new direction for drug discovery
Jul 05, 2009 |
not rated yet |
0
-
Of mice and mental models: Neuroscientific implications of risk-optimized behavior in the mouse
May 25, 2012 |
not rated yet |
0
-
Limits to growth: Scientists identify key metastasis-enabling enzyme
May 22, 2012 |
5 / 5 (4) |
0
-
Seeing is as seeing does: Spatially-structured retinal input in early development of cortical maps
Apr 26, 2012 |
5 / 5 (4) |
1
-
Dreamless nights: Brain activity during nonrapid eye movement sleep
Apr 09, 2012 |
4.4 / 5 (12) |
0
-
Take your time: Neurobiology sheds light on the superiority of spaced vs. massed learning
Mar 28, 2012 |
4.5 / 5 (21) |
3
-
Potential Breakthrough in Seizure Control
17 hours ago
-
Popping/Cracked sternum.
22 hours ago
-
Which Mental Illness Encompasses This Problem?
22 hours ago
-
A question about drug tolerance
May 23, 2012
-
Poor nutrition leading to overeating?
May 23, 2012
-
Math and dyslexia?
May 21, 2012
- More from Physics Forums - Medical Sciences
More news stories
Skp2 activates cancer-promoting, glucose-processing Akt
HER2 and its epidermal growth factor receptor cousins mobilize a specialized protein to activate a major player in cancer development and sugar metabolism, scientists report in the May 25 issue of Cell.
Cancer
May 25, 2012 |
not rated yet |
0
|
Pancreatectomy OK without downstaging from therapy
(HealthDay) -- Pancreatectomy improves median survival in pancreatic cancer patients even when presurgical neoadjuvant therapy does not lead to radiographic downstaging of tumors, according to a study published ...
Cancer
May 25, 2012 |
not rated yet |
0
Common therapies for basal cell carcinoma offer similar survival
(HealthDay) -- For patients with superficial basal cell carcinoma (sBCC), treatment with imiquimod or photodynamic therapy (PDT) results in similar long-term tumor-free survival, according to a review published ...
Cancer
May 25, 2012 |
not rated yet |
0
Cancer may require simpler genetic mutations than previously thought
Chromosomal deletions in DNA often involve just one of two gene copies inherited from either parent. But scientists haven't known how a deletion in one gene from one parent, called a "hemizygous" deletion, can contribute ...
Cancer
May 25, 2012 |
not rated yet |
0
|
New prostate cancer screening guidelines face a tough sell, study suggests
(Medical Xpress) -- Recent recommendations from the U.S. Preventive Services Task Force (USPSTF) advising elimination of routine prostate-specific antigen (PSA) screening for prostate cancer in healthy men are likely to encounter ...
Cancer
May 25, 2012 |
not rated yet |
1
Keep food safety in mind this memorial day weekend
(HealthDay) -- Picnics, parades and cookouts are as much a part of Memorial Day weekend as tributes to the United States' war veterans.
Travel to high altitudes tied to Crohn's, colitis flare-ups
(HealthDay) -- People with inflammatory bowel disease, which includes Crohn's disease and colitis, may be at increased risk for flare-ups when they fly or travel to high altitudes for skiing or mountain climbing, ...
Family history of Alzheimer's affects functional connectivity
(HealthDay) -- Cognitively normal individuals with a family history of late-onset Alzheimer's disease (AD) may display lower resting state functional connectivity in the default mode network (DMN) of the brain, ...
Transvaginal mesh op restores pelvic organ prolapse at price
(HealthDay) -- Transvaginal mesh (TVM) procedures are effective for anatomical restoration of pelvic organ prolapse (POP), but patients report a worsening of sexual function following surgery, according to ...
Of mice and mental models: Neuroscientific implications of risk-optimized behavior in the mouse
(Medical Xpress) -- Regardless of an organism’s biological complexity, every encephalized animal continuously makes under-informed behavioral choices that can have serious consequences. Despite its ubiquity, ...
Weight struggles? Blame new neurons in your hypothalamus
New nerve cells formed in a select part of the brain could hold considerable sway over how much you eat and consequently weigh, new animal research by Johns Hopkins scientists suggests in a study published in the May issue ...